Donald E. Bobo Jr - May 5, 2023 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP,Strategy/Corp Development
Signature
Linda J. Park, Attorney-in-Fact
Stock symbol
EW
Transactions as of
May 5, 2023
Transactions value $
-$886,929
Form type
4
Date filed
5/8/2023, 09:54 PM
Previous filing
May 4, 2023
Next filing
May 11, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Sale -$499K -5.64K -9.11% $88.63 56.2K May 5, 2023 Direct
transaction EW Common Stock Options Exercise $0 +4.77K +8.48% $0.00 61K May 7, 2023 Direct F1
transaction EW Common Stock Tax liability -$263K -2.97K -4.87% $88.74 58K May 7, 2023 Direct
transaction EW Common Stock Tax liability -$124K -1.4K -2.41% $88.74 56.6K May 8, 2023 Direct
holding EW Common Stock 38.4K May 5, 2023 401(k)
holding EW Common Stock 112K May 5, 2023 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Performance Rights Options Exercise $0 -4.77K -78.47% $0.00 1.31K May 7, 2023 Common Stock 4.77K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.